Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 12 (1), 61-5

Making Better Influenza Virus Vaccines?

Affiliations
Review

Making Better Influenza Virus Vaccines?

Peter Palese. Emerg Infect Dis.

Abstract

Killed and live influenza virus vaccines are effective in preventing and curbing the spread of disease, but new technologies such as reverse genetics could be used to improve them and to shorten the lengthy process of preparing vaccine seed viruses. By taking advantage of these new technologies, we could develop live vaccines that would be safe, cross-protective against variant strains, and require less virus per dose than conventional vaccines. Furthermore, pandemic vaccines against highly virulent strains such as the H5N1 virus can only be generated by reverse genetics techniques. Other technologic breakthroughs should result in effective adjuvants for use with killed and live vaccines, increasing the number of available doses. Finally, universal influenza virus vaccines seem to be within reach. These new strategies will be successful if they are supported by regulatory agencies and if a robust market for influenza virus vaccines against inter-pandemic and pandemic threats is made and sustained.

Similar articles

See all similar articles

Cited by 50 PubMed Central articles

See all "Cited by" articles

References

    1. Gerin JL, Anderson NG Purification of influenza virus in the K-II zonal centrifuge. Nature. 1969;221:1255–6 10.1038/2211255a0 - DOI - PubMed
    1. World Health Organization Recommendations for influenza vaccine composition. [cited 2005 Nov 10]. Available from http://www.who.int/csr/disease/influenza/vaccinerecommendations1/en/
    1. Centers for Disease Control and Prevention Update: Influenza Activity United States, 2004–05 Season. [cited 2005 Nov 10]. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5408a1.htm
    1. Kilbourne ED Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ. 1969;41:643–5 - PMC - PubMed
    1. Maassab H, Heilman C, Herlocher M Cold-adapted influenza viruses for use as live vaccines for man. Adv Biotechnol Processes. 1990;14:203–42 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback